Private payer-negotiated prices for FDA-approved biologic treatments for allergic diseases
Int Forum Allergy Rhinol
.
2022 May;12(5):798-801.
doi: 10.1002/alr.22922.
Epub 2021 Nov 24.
Authors
Annette A Wang
1
,
Vinay K Rathi
2
3
,
Roy Xiao
2
3
,
Eric H Holbrook
2
3
,
George A Scangas
2
3
,
Alan D Workman
2
3
,
Stacey T Gray
2
3
Affiliations
1
Harvard Medical School, Boston, Massachusetts, USA.
2
Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
3
Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts, USA.
PMID:
34821065
DOI:
10.1002/alr.22922
No abstract available
Keywords:
allergic rhinitis; asthma; chronic rhinosinusitis.
MeSH terms
Biological Products* / therapeutic use
Humans
Hypersensitivity* / drug therapy
Substances
Biological Products